Navigation Links
Patent Issued In China For EntreMed's Lead Drug Candidate ENMD-2076
Date:5/6/2013

Phase 2 study of ENMD-2076 in triple-negative breast cancer and a Phase 2 study in advanced/metastatic soft tissue sarcoma. ENMD-2076 has received orphan drug designation from the FDA for the treatment of ovarian cancer, multiple myeloma and acute myeloid leukemia.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals.  Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; the difficulty of executing our business strategy in China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidate or future candidates; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; declines in actual sales of Thalomid® resulting in reduced or no royalty payments; risks associated with our product candidates; any early-stage products under development; results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Mapi Pharma Granted United States Patent Covering Glatiramer Depot for Multiple Sclerosis
2. Patent Issued In U.S. For EntreMeds 2ME2 In Rheumatoid Diseases
3. Catabasis Pharmaceuticals Announces Issuance of Patents for CAT-1000 and CAT-2000 Series
4. Dr. Isaac Eliaz Awarded Patent for Modified Citrus Pectin and Alginates
5. Absorption Pharmaceuticals to Receive Patent for Premature Ejaculation Topical Medication
6. LamdaGen Corporation Issued United States Patent for Diagnostics on Plasmonic-Based Nanosensors
7. Fuisz Pharma Announces Intent to Divest Strategic Patent for Detection of Opioid Abuse; Seeks Offers for Patent through May 2013
8. Bioinformatics Market: Technologies, Patenting Trends & 2017 Forecasts
9. Neuralstem Receives Notice Of Allowance Of Patent Covering Use Of Stem Cells To Treat Amyotrophic Lateral Sclerosis
10. VolitionRx Files Two Patent Applications
11. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Decision Resources Group finds that over half ... and Drug Administration,s (FDA) approval of Vifor Fresenius Medical ... approved by the FDA in November 2013 for the ... on dialysis. Other key findings from the ... : , Bundling: ...
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds ... its store . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ... upgrade and policy support, China,s ... years, with total market size rising from 3.28 billion ...
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
(Date:7/13/2014)... July 13, 2014 A Massachusetts couple ... the cancer risks associated with power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ... story to federal regulators, as they presented poignant testimony ... & Drug Administration (FDA) advisory panel meeting convened to ... to the Rochester Democrat and Chronicle, Dr. Hooman Noorchashm ...
(Date:7/13/2014)... York, New York (PRWEB) July 13, 2014 ... lawsuits ( http://www.transvaginalmeshlawsuithelp.com/ ) filed against Johnson ... litigation’s second bellwether trial, which is expected to get ... Order issued in the U.S. District Court, Southern District ... Conference will be held on August 7, 2014 at ...
(Date:7/13/2014)... Fadhits.com is popular among worldwide women. ... extremely beautiful. Recently, the company has announced its new ... What’s more, all these outfits are available at discounted ... Additionally, the supplier is now offering similar discounts for ... it has many other designs for sale, including flower ...
(Date:7/13/2014)... According to the Kidney Disease Solution book review recently updated ... what to do to eliminate the root cause of ... review that readers can easily learn what foods to avoid ... Vkool also informs in its Kidney Disease Solution review that ... naturally. The book consists of a collection of natural remedies ...
(Date:7/13/2014)... Seattle, WA (PRWEB) July 13, 2014 ... Ken Woolcott, who commented, “As a parent of a ... the underserved need in the Seattle community for contemporary ... will provide an important alternative to students and families ... the best practices and environment for special education. We ...
Breaking Medicine News(10 mins):Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 2Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 3Health News:New Private School, Emerald City School, Founded in Downtown Seattle Now Accepting 1st to 6th Grade Students Who Learn Differently 2
... study says , , TUESDAY, Oct. 28 (HealthDay News) -- A ... to the immune system of people aged 65 and older ... study that included nearly 4,000 people. , Blood tests showed ... the standard flu vaccine had 30 percent to 80 percent ...
... Trials on Schedule, HAIKOU CITY, China, ... ("China Pharma") (OTC Bulletin Board: CPHI), which,develops, ... in China, announced today that its novel ... China,s State Food and Drug,Administration (SFDA) to ...
... December 5, 2008, Alta,Bates Summit Medical Center,s Markstein ... their Summit Campus (3100 Summit Street,Oakland, CA, 94609). ... Foundation, a San Francisco Bay Area non-profit dedicated ... a time. Sponsoring this screening,is part of the ...
... SAN FRANCISCO, Calif., Oct. 29 Rigel,Pharmaceuticals, Inc. (Nasdaq: ... vice president and chief operating officer, will present,a company ... November 3 at 3:20 p.m. EST at The Waldorf ... live audio webcast or the subsequent archived recording,log on ...
... 2008 at this year,s liver meeting ... SAN FRANCISCO, Oct. 29 Two studies presented at the,annual ... Diseases,paint a different picture of survival based on racial group ... the Baylor College of Medicine used a United Network for,Organ ...
... GAAP diluted earnings per share from continuing operations decline 16 ... basis ... ... a,global provider of products and services that improve the safety and,productivity of health ...
Cached Medicine News:Health News:High-Dose Flu Shot Benefits Elderly 2Health News:China Pharma Holdings, Inc. to Initiate Clinical Trials For New Antibiotic Combination 2Health News:China Pharma Holdings, Inc. to Initiate Clinical Trials For New Antibiotic Combination 3Health News:Lazarex Cancer Foundation Sponsors Community Colorectal Cancer Screening at Alta Bates Summit Medical Center 2Health News:No Difference in Rate of Survival for Children of Different Races Undergoing Liver Transplantation, but Long-Term Results Not as Good for African-American Adults 2Health News:No Difference in Rate of Survival for Children of Different Races Undergoing Liver Transplantation, but Long-Term Results Not as Good for African-American Adults 3Health News:Cardinal Health Reports First Quarter Results 2Health News:Cardinal Health Reports First Quarter Results 3Health News:Cardinal Health Reports First Quarter Results 4Health News:Cardinal Health Reports First Quarter Results 5Health News:Cardinal Health Reports First Quarter Results 6Health News:Cardinal Health Reports First Quarter Results 7Health News:Cardinal Health Reports First Quarter Results 8Health News:Cardinal Health Reports First Quarter Results 9Health News:Cardinal Health Reports First Quarter Results 10Health News:Cardinal Health Reports First Quarter Results 11Health News:Cardinal Health Reports First Quarter Results 12Health News:Cardinal Health Reports First Quarter Results 13Health News:Cardinal Health Reports First Quarter Results 14Health News:Cardinal Health Reports First Quarter Results 15Health News:Cardinal Health Reports First Quarter Results 16Health News:Cardinal Health Reports First Quarter Results 17Health News:Cardinal Health Reports First Quarter Results 18Health News:Cardinal Health Reports First Quarter Results 19Health News:Cardinal Health Reports First Quarter Results 20Health News:Cardinal Health Reports First Quarter Results 21Health News:Cardinal Health Reports First Quarter Results 22Health News:Cardinal Health Reports First Quarter Results 23
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: